- CP Indonesia’s net income for the first half of 2024 is 1.77 trillion rupiah, a 28% increase from the same period last year.
- Last year’s net income was 1.38 trillion rupiah.
- CP Indonesia’s earnings per share (EPS) rose to 108 rupiah from 84 rupiah year over year.
- Net sales for the first half of 2024 reached 32.96 trillion rupiah, growing by 6.7% compared to the previous year.
- Investment analysts’ ratings: 12 buys, 6 holds, and 0 sells.
A look at Charoen Pokphand Indonesia Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have assessed Charoen Pokphand Indonesia‘s long-term outlook using Smart Scores, with the company scoring well across multiple factors. With a solid Growth score of 4 and Momentum score of 4, Charoen Pokphand Indonesia is positioned for positive development and market performance in the coming years. This indicates the company’s potential for expansion and its ability to maintain upward momentum in the market.
Additionally, Charoen Pokphand Indonesia has received a respectable Dividend score of 3, signaling its capability to provide dividend returns to its investors. The company’s overall resilience score of 3 further suggests a reasonable level of stability and ability to withstand market fluctuations. While the Value score is at 2, Charoen Pokphand Indonesia‘s strengths in growth, momentum, dividend, and resilience aspects paint a promising picture for its future prospects.
### Summary: PT Charoen Pokphand Indonesia Tbk manufactures and distributes animal feeds, woven plastic bags, and poultry equipment as well as processes chicken. Through its subsidiaries, the Company also operates poultry farms and distributes its products. ###
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
